Novartis joined Pharma.Aero as a member of the Life Sciences Manufacturers Advisory Platform (LMAP), in August 2023. The Advisory Platform was created to further engage the manufacturing segment to provide first-line advice on the activities and projects of Pharma.Aero and support the logistics and supply chain industry. The LMAP integrates into all Pharma.Aero cross-industry initiatives and provide content value to the organization.

Novartis’ decision to elevate its role within Pharma.Aero underscores the company’s dedication to staying at the forefront of emerging trends and addressing industry challenges head-on. As a Strategic Member, Novartis becomes a voting member of the General Assembly and can run for a position on the Board of Directors.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. They deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In their quest to find new medicines, Novartis consistently rank among the world’s top companies investing in research and development. Over 100,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com.